Cargando…

A prospective comparison of perioperative morbidity in advanced epithelial ovarian cancer: Primary versus interval cytoreduction - experience from India

OBJECTIVES: The objective was to compare perioperative morbidity and mortality of patients with advanced epithelial ovarian cancer (EOC) treated with either of the two treatment approaches; neoadjuvant chemotherapy (NACT) followed by interval debulking versus upfront surgery. DESIGN: Prospective com...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmad, Sheikh Zahoor, Rajanbabu, Anupama, Vijaykumar, D. K., Haji, Altaf Gauhar, Pavithran, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4756482/
https://www.ncbi.nlm.nih.gov/pubmed/26942138
http://dx.doi.org/10.4103/2278-330X.173171
_version_ 1782416340183678976
author Ahmad, Sheikh Zahoor
Rajanbabu, Anupama
Vijaykumar, D. K.
Haji, Altaf Gauhar
Pavithran, K.
author_facet Ahmad, Sheikh Zahoor
Rajanbabu, Anupama
Vijaykumar, D. K.
Haji, Altaf Gauhar
Pavithran, K.
author_sort Ahmad, Sheikh Zahoor
collection PubMed
description OBJECTIVES: The objective was to compare perioperative morbidity and mortality of patients with advanced epithelial ovarian cancer (EOC) treated with either of the two treatment approaches; neoadjuvant chemotherapy (NACT) followed by interval debulking versus upfront surgery. DESIGN: Prospective comparative observational study. PARTICIPANTS: In total, 51 patients were included in the study. All patients with diagnosed advanced EOC (International Federation of Gynecology and Obstetrics IIIC and IV) presenting for the 1(st) time were included in the study. INTERVENTIONS: Patients were either operated upfront (n = 19) if deemed operable or were subjected to NACT followed by interval debulking (n = 32). PRIMARY AND SECONDARY OUTCOMES: Intra- and postoperative morbidity and mortality were the primary outcome measures. RESULTS: Patients with interval cytoreduction were noted to have significantly lesser operative time, blood loss, and extent of surgery. Their discharge time was also significantly earlier. However, they did not differ from the other group vis. a vis. postoperative complications or mortality. CONCLUSIONS: Neoadjuvant chemotherapy although has a positive impact on various intraoperative adverse events, fails to show any impact on immediate postoperative negative outcomes.
format Online
Article
Text
id pubmed-4756482
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-47564822016-03-03 A prospective comparison of perioperative morbidity in advanced epithelial ovarian cancer: Primary versus interval cytoreduction - experience from India Ahmad, Sheikh Zahoor Rajanbabu, Anupama Vijaykumar, D. K. Haji, Altaf Gauhar Pavithran, K. South Asian J Cancer GENITOURINARY: Original Article OBJECTIVES: The objective was to compare perioperative morbidity and mortality of patients with advanced epithelial ovarian cancer (EOC) treated with either of the two treatment approaches; neoadjuvant chemotherapy (NACT) followed by interval debulking versus upfront surgery. DESIGN: Prospective comparative observational study. PARTICIPANTS: In total, 51 patients were included in the study. All patients with diagnosed advanced EOC (International Federation of Gynecology and Obstetrics IIIC and IV) presenting for the 1(st) time were included in the study. INTERVENTIONS: Patients were either operated upfront (n = 19) if deemed operable or were subjected to NACT followed by interval debulking (n = 32). PRIMARY AND SECONDARY OUTCOMES: Intra- and postoperative morbidity and mortality were the primary outcome measures. RESULTS: Patients with interval cytoreduction were noted to have significantly lesser operative time, blood loss, and extent of surgery. Their discharge time was also significantly earlier. However, they did not differ from the other group vis. a vis. postoperative complications or mortality. CONCLUSIONS: Neoadjuvant chemotherapy although has a positive impact on various intraoperative adverse events, fails to show any impact on immediate postoperative negative outcomes. Medknow Publications & Media Pvt Ltd 2015 /pmc/articles/PMC4756482/ /pubmed/26942138 http://dx.doi.org/10.4103/2278-330X.173171 Text en Copyright: © South Asian Journal of Cancer http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle GENITOURINARY: Original Article
Ahmad, Sheikh Zahoor
Rajanbabu, Anupama
Vijaykumar, D. K.
Haji, Altaf Gauhar
Pavithran, K.
A prospective comparison of perioperative morbidity in advanced epithelial ovarian cancer: Primary versus interval cytoreduction - experience from India
title A prospective comparison of perioperative morbidity in advanced epithelial ovarian cancer: Primary versus interval cytoreduction - experience from India
title_full A prospective comparison of perioperative morbidity in advanced epithelial ovarian cancer: Primary versus interval cytoreduction - experience from India
title_fullStr A prospective comparison of perioperative morbidity in advanced epithelial ovarian cancer: Primary versus interval cytoreduction - experience from India
title_full_unstemmed A prospective comparison of perioperative morbidity in advanced epithelial ovarian cancer: Primary versus interval cytoreduction - experience from India
title_short A prospective comparison of perioperative morbidity in advanced epithelial ovarian cancer: Primary versus interval cytoreduction - experience from India
title_sort prospective comparison of perioperative morbidity in advanced epithelial ovarian cancer: primary versus interval cytoreduction - experience from india
topic GENITOURINARY: Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4756482/
https://www.ncbi.nlm.nih.gov/pubmed/26942138
http://dx.doi.org/10.4103/2278-330X.173171
work_keys_str_mv AT ahmadsheikhzahoor aprospectivecomparisonofperioperativemorbidityinadvancedepithelialovariancancerprimaryversusintervalcytoreductionexperiencefromindia
AT rajanbabuanupama aprospectivecomparisonofperioperativemorbidityinadvancedepithelialovariancancerprimaryversusintervalcytoreductionexperiencefromindia
AT vijaykumardk aprospectivecomparisonofperioperativemorbidityinadvancedepithelialovariancancerprimaryversusintervalcytoreductionexperiencefromindia
AT hajialtafgauhar aprospectivecomparisonofperioperativemorbidityinadvancedepithelialovariancancerprimaryversusintervalcytoreductionexperiencefromindia
AT pavithrank aprospectivecomparisonofperioperativemorbidityinadvancedepithelialovariancancerprimaryversusintervalcytoreductionexperiencefromindia
AT ahmadsheikhzahoor prospectivecomparisonofperioperativemorbidityinadvancedepithelialovariancancerprimaryversusintervalcytoreductionexperiencefromindia
AT rajanbabuanupama prospectivecomparisonofperioperativemorbidityinadvancedepithelialovariancancerprimaryversusintervalcytoreductionexperiencefromindia
AT vijaykumardk prospectivecomparisonofperioperativemorbidityinadvancedepithelialovariancancerprimaryversusintervalcytoreductionexperiencefromindia
AT hajialtafgauhar prospectivecomparisonofperioperativemorbidityinadvancedepithelialovariancancerprimaryversusintervalcytoreductionexperiencefromindia
AT pavithrank prospectivecomparisonofperioperativemorbidityinadvancedepithelialovariancancerprimaryversusintervalcytoreductionexperiencefromindia